首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

1378670

帕金森氏症藥物市場：依藥物類別、給藥途徑、配銷通路和地區

Parkinsons Disease Therapeutics Market, By Drug Class (Levodopa, Dopamine agonists, MAO-B inhibitors, Anticholinergics, Others ), By Route of Administration (Oral, Injectable, Nasal, Transdermal, Others ), By Distribution Channel, By Geography

出版日期: 2023年10月10日 | 出版商:

Coherent Market Insights | 英文 312 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2023 年，全球帕金森氏症治療市場將達到 51.1 億美元，預計在預測期內（2023-2030 年）年複合成長率為 7.0%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	51.1億美元
實績資料	2018-2021	預測期	2023-2030
預測期年複合成長率	7.00%	2030年市場規模預測	82億美元

圖 1. 2023 年帕金森氏症藥物的全球市場佔有率(%)（依藥物類別）

帕金森氏症是一種由神經系統疾病引起的運動障礙。震顫、運動緩慢、肌肉僵硬、步態不穩定以及平衡和協調問題都是帕金森氏症的常見症狀。左旋多巴、多巴胺促效劑、MAO-B 抑制劑和抗膽鹼能藥物是一些用於治療帕金森氏症的藥物。左旋多巴（也稱為左旋多巴）是治療帕金森氏症最常用的處方藥。左旋多巴可有效控制諸如運動緩慢和身體某些部位僵硬或僵硬等症狀。大多數患者可以透過藥物治療維持高品質的生活，對於某些患者來說，症狀可以透過手術來改善。另一種稱為去甲腎上腺素的神經傳導物質在帕金森氏症患者中也會減少。該分子是交感神經系統正常運作所必需的。身體的一些自主神經活動，如消化、心率、血壓和呼吸，都是由這個系統控制的。帕金森氏症的一些非運動症狀是由於去甲腎上腺素缺乏所引起的。運動可以顯著改善帕金森氏症的症狀。物理、職業和語言治療還可以改善步態和平衡問題、飲食和吞嚥障礙以及語言障礙。

市場動態

市場參與者正專注於推出新產品，預計這將在預測期內推動帕金森氏症藥物市場的成長。例如，2020年5月，美國公司Sunovion Pharmaceuticals Inc.推出了KYNMOBI（阿樸嗎啡嗎啡）舌下膜，作為帕金森氏症患者OFF發作（即PD症狀復發或惡化）的急性間歇治療。食品藥物管理局核准。 KYNMOBI 有不同的規格：10 毫克、15 毫克、20 毫克和 25 毫克。

本研究的主要特點

本報告對全球帕金森氏症藥物市場進行了詳細分析，並呈現了以2022年為基準年的預測期（2023-2030年）的市場規模和複合年度（年複合成長率）。
本報告還揭示各個區隔市場的潛在商機，並為該市場說明了一系列有吸引力的投資提案。
本報告還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。
它根據公司亮點、產品系列、主要亮點、財務實績和策略等參數，介紹了全球帕金森氏症治療藥物市場的主要企業。
該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的資訊。
全球帕金森氏症治療藥物市場報告針對該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
透過用於分析全球帕金森氏症治療藥物市場的各種策略矩陣，將有助於相關人員做出決策。

公司簡介
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- GlaxoSmithKline Plc.
- AbbVie Inc.
- Merck &Co., Inc.
- Zydus Cadila
- Dr. Reddy's Laboratories
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Boehringer Ingelheim International GmbH
- Denali Therapeutics Inc.
- Biogen Inc.
- Prevail Therapeutics
- Eli Lilly and Company
- Voyager Therapeutics

第10章章

參考
調查方法

簡介目錄

Product Code: CMI494

The global Parkinsons disease therapeutics market is estimated to be valued at US$ 5.11 Billion in 2023 and is expected to exhibit a CAGR of 7.0% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 5.11 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	7.00%	2030 Value Projection:	US$ 8.2 Bn

Figure 1. Global Parkinsons Disease Therapeutics Market Share (%), By Drug Class, 2023

Parkinsons Disease Therapeutics Market - IMG1

Parkinsons disease is a movement disorder caused by a neurological condition. Tremor, slowness of movement, tight muscles, an unsteady walk, balance, and coordination issues are all common symptoms of Parkinson disease. Levodopa, dopamine agonists, MAO-B inhibitors, and anticholinergics are some of the medications used for the treatment of Parkinson's disease. Levodopa (also called L-dopa) is the most commonly prescribed drug for Parkinson's disease. It is useful in controlling symptoms such as slow movements and stiff and rigid body parts. Medication allows the majority of patients to retain a high quality of life, and surgery can help some people improve their symptoms. Parkinson's disease patients also observe a decrease in another neurotransmitter known as norepinephrine. This molecule is required for the sympathetic nervous system to operate properly. Some of the body's autonomic activities are controlled by this system, including digestion, heart rate, blood pressure, and breathing. Some of the non-movement-related symptoms of Parkinson's disease are caused by a lack of norepinephrine. Exercise can considerably improve Parkinson's symptoms. Physical therapy, occupational therapy, and speech-language therapy can also assist with walking and balance issues, eating and swallowing difficulties, and speech disorders.

Market Dynamics

Market players are focusing on new product launches, which is expected to propel the Parkinsons disease therapeutic market growth during the forecast period. For instance, in May 2020, Sunovion Pharmaceuticals Inc., a pharmaceutical company, announced that it received U.S. Food and Drug Administration (FDA) approval for KYNMOBI (apomorphine hydrochloride) sublingual film for the acute, intermittent treatment for OFF episodes (i.e., re-emergence or worsening of PD symptoms) in patients with Parkinson's disease. KYNMOBI is available in different strengths, such as 10mg, 15mg, 20mg, and 25mg.

Key features of the study:

This report provides an in-depth analysis of the global Parkinsons disease therapeutic market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global Parkinsons disease therapeutic market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline Plc., AbbVie Inc., Merck & Co., Inc., Zydus Cadila, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries Ltd., Cipla Inc., Boehringer Ingelheim International GmbH, Denali Therapeutics Inc., Biogen Inc., Prevail Therapeutics, Eli Lilly and Company and Voyager Therapeutics
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global Parkinsons disease therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Parkinsons disease therapeutic market.

Detailed Segmentation:

By Drug Class:
- Levodopa
- Dopamine agonists
- MAO-B inhibitors
- Anticholinergics
- Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine, among Others)
By Route of Admnistration:
- Oral
- Injectable
- Nasal
- Transdermal
- Others (Rectal, Sublingual, among Others)
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Company Profiles
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- GlaxoSmithKline Plc.
- AbbVie Inc.
- Merck & Co., Inc.
- Zydus Cadila
- Dr. Reddy's Laboratories
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Boehringer Ingelheim International GmbH
- Denali Therapeutics Inc.
- Biogen Inc.
- Prevail Therapeutics
- Eli Lilly and Company
- Voyager Therapeutics.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics

Drivers
Restraints
Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis

4. Global Parkinsons Disease Therapeutics Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Parkinsons Disease Therapeutics Market, By Drug Class, 2018- 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Levodopa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Dopamine agonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
MAO-B inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Anticholinergics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine, among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

6. Global Parkinsons Disease Therapeutics Market, By Route of Administration, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Nasal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
Others (Rectal, Sublingual, among Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends

7. Global Parkinsons Disease Therapeutics Market, By Distribution Channel, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global Parkinsons Disease Therapeutics Market, By Region, 2018-2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 -2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Bn)
- `Market Size and Forecast, Y-o-Y Growth and By Route of Administration, 2018 -2030, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2018 -2030, (US$ Bn)
North Africa
Central Africa
South Africa

9. Competitive Landscape

Company Profiles
- Teva Pharmaceutical Industries Ltd.*
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Novartis AG
- GlaxoSmithKline Plc.
- AbbVie Inc.
- Merck & Co., Inc.
- Zydus Cadila
- Dr. Reddy's Laboratories
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Boehringer Ingelheim International GmbH
- Denali Therapeutics Inc.
- Biogen Inc.
- Prevail Therapeutics
- Eli Lilly and Company
- Voyager Therapeutics